Psychological factors predict adherence to methotrexate in rheumatoid arthritis; Findings from a systematic review of rates, predictors and associations with patient-reported and clinical outcomes

RMD Open

Volumn 2, Issue 1, 2016, Pages

  Hope, Holly F ^a   Bluett, James ^a,b   Barton, Anne ^a,b   Hyrich, Kimme L ^b   Cordingley, Lis ^b   Verstappen, Suzanne M M ^b  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84988353382     PISSN: None     EISSN: 20565933     Source Type: Journal    
DOI: 10.1136/rmdopen-2015-000171     Document Type: Article

References (40)

1. Maetzel A, Wong A, Strand VS, et al. Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. Rheumatology (Oxford) 2000;39:975-81.
2. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.
3. National Institute for Health and Care Excellence. Rheumatoid arthritis: the management of rheumatoid arthritis in adults. CG79. Manchester: NICE, 2009.
4. Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008;372:375-82.
5. Emery P, Burmester GR, Bykerk VP, et al. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis 2015;74:19-26.
6. Hider SL, Silman A, Bunn D, et al. Comparing the long-term clinical outcome of treatment with methotrexate or sulfasalazine prescribed as the first disease-modifying antirheumatic drug in patients with inflammatory polyarthritis. Ann Rheum Dis 2006;65:1449-55.
7. The World Health Organisation. Adherence to long-term therapies: evidence for action. 2003. http://www.who.int/chp/knowledge/ publications/adherence-full-report.pdf?ua=1 (accessed March 2013).
8. Trueman P, Taylor DG, Lowson K, et al. Evaluation of the scale, causes and costs of waste medicines. Report of DH funded national project. YHEC/The School of Pharmacy, University of London. 2010.
9. Cramer J, Rosenheck R, Kirk G, et al. VA Naltrexone Study Group. Medication compliance feedback and monitoring in a clinical trial: predictors and outcomes. Value Health 2003;6:566-73.
10. Haynes RB, McDonald HP, Garg AX. Helping patients follow prescribed treatment: clinical applications. JAMA 2002;288:2880-3.
11. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002;288:462-7.
12. Pasma A, van't Spijker A, Hazes JM, et al. Factors associated with adherence to pharmaceutical treatment for rheumatoid arthritis patients: a systematic review. Semin Arthritis Rheum 2013;43:18-28.
13. Fidder HH, Singendonk MM, van der Have M, et al. Low rates of adherence for tumor necrosis factor-alpha inhibitors in Crohn's disease and rheumatoid arthritis: results of a systematic review. World J Gastroenterol 2013;19:4344-50.
14. Blum MA, Koo D, Doshi JA. Measurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: a systematic review. Clin Ther 2011;33:901-13.
15. de Achaval SD, Suarez-Almazor ME. Treatment adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and systemic lupus erythematosus. Int J Clin Rheumtol 2010;5:313-26.
16. Koncz T, Pentek M, Brodszky VS, et al. Adherence to biologic DMARD therapies in rheumatoid arthritis. Expert Opin Biol Ther 2010;10:1367-78.
17. Harrold LR, Andrade SE. Medication adherence of patients with selected rheumatic conditions: a systematic review of the literature. Semin Arthritis Rheum 2009;38:396-402.
18. da Costa Santos CM, de Mattos Pimenta CA, Nobre MR. The PICO strategy for the research question construction and evidence search. Rev Lat Am Enfermagem 2007;15:508-11.
19. Sanderson S, Tatt ID, Higgins JP. Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography. Int J Epidemiol 2007;36:666-76.
20. van Tulder M, Furlan A, Bombardier C, et al. Updated method guidelines for systematic reviews in the Cochrane collaboration back review group. Spine 2003;28:1290-9.
21. Harley CR, Frytak JR, Tandon N. Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. Am J Manag Care 2003;9(6 Suppl):S136-43.
22. de Klerk E, van der Heijde D, Landewe R, et al. Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout. J Rheumatol 2003;30:44-54.
23. Grijalva CG, Chung CP, Arbogast PG, et al. Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis. Med Care 2007;45(Suppl 2):S66-76.
24. Contreras-Yanez I, Ponce de Leon S, Cabiedes J, et al. Inadequate therapy behavior is associated to disease flares in patients with rheumatoid arthritis who have achieved remission with diseasemodifying antirheumatic drugs. Am J Med Sci 2010;340:282-90.
25. Grijalva CG, Kaltenbach L, Arbogast PG, et al. Adherence to disease-modifying antirheumatic drugs and the effects of exposure misclassification on the risk of hospital admission. Arthritis Care Res (Hoboken) 2010;62:730-4.
26. de Thurah A, Norgaard M, Johansen MB, et al. Methotrexate compliance among patients with rheumatoid arthritis: the influence of disease activity, disease duration, and co-morbidity in a 10-year longitudinal study. Scand J Rheumatol 2010;39:197-205.
27. de Thurah A, Norgaard M, Harder I, et al. Compliance with methotrexate treatment in patients with rheumatoid arthritis: influence of patients' beliefs about the medicine. A prospective cohort study. Rheumatol Int 2010;30:1441-8.
28. Cannon GW, Mikuls TR, Hayden CL, et al. Merging Veterans Affairs rheumatoid arthritis registry and pharmacy data to assess methotrexate adherence and disease activity in clinical practice. Arthritis Care Res (Hoboken) 2011;63:1680-90.
29. Salt E, Frazier SK. Predictors of medication adherence in patients with rheumatoid arthritis. Drug Dev Res 2011;72:756-63.
30. Waimann CA, Marengo MF, de Achaval S, et al. Electronic monitoring of oral therapies in ethnically diverse and economically disadvantaged patients with rheumatoid arthritis: consequences of low adherence. Arthritis Rheum 2013;65:1421-9.
31. Quittner AL, Modi AC, Lemanek KL, et al. Evidence-based assessment of adherence to medical treatments in pediatric psychology. J Pediatr Psychol 2008;33:916-36.
32. Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res 1999;47:555-67.
33. de Klerk E, van der Heijde D, Landewe R, et al. The compliance-questionnaire-rheumatology compared with electronic medication event monitoring: a validation study. J Rheumatol 2003;30:2469-75.
34. Godfrey C, Sweeney K, Miller K, et al. The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis. Br J Clin Pharmacol 1998;46:369-76.
35. Miller W, Rollnick S. Motivational interviewing. New York: Guilford Press, 1999.
36. Horne R. Patients' beliefs about treatment: the hidden determinant of treatment outcome? J Psychosom Res 1999;47:491-5.
37. Neame R, Hammond A. Beliefs about medications: a questionnaire survey of people with rheumatoid arthritis. Rheumatology (Oxford) 2005;44:762-7.
38. Haynes RB, Ackloo E, Sahota N, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008;(2): CD000011.
39. DiMatteo MR, Haskard KB, Williams SL. Health beliefs, disease severity, and patient adherence: a meta-analysis. Med Care 2007;45:521-8.
40. Hoekstra M, van Ede AE, Haagsma CJ, et al. Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis 2003;62:423-6.